

CITATION REPORT

List of articles citing

Catalyzing the Critical Path Initiative: FDA's progress in drug development activities

DOI: 10.1002/cpt.42

Clinical Pharmacology and Therapeutics, 2015, 97, 221-33.

Source: <https://exaly.com/paper-pdf/60755978/citation-report.pdf>

Version: 2024-04-09

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
28	Biomarker Qualification: Toward a Multiple Stakeholder Framework for Biomarker Development, Regulatory Acceptance, and Utilization. <i>Clinical Pharmacology and Therapeutics</i> , 2015 , 98, 34-46	6.1	132
27	Building a roadmap to biomarker qualification: challenges and opportunities. <i>Biomarkers in Medicine</i> , 2015 , 9, 1095-105	2.3	40
26	Non-Alcoholic Steatohepatitis: Limited Available Treatment Options but Promising Drugs in Development and Recent Progress Towards a Regulatory Approval Pathway. <i>Drugs</i> , 2015 , 75, 1373-92	12.1	50
25	Biomarkers to guide clinical therapeutics in rheumatology?. <i>Current Opinion in Rheumatology</i> , 2016 , 28, 168-75	5.3	30
24	Translatable Biomarkers in Drug Development. 2016 , 500-507		
23	Perspectives in regulatory science: translational and clinical pharmacology. <i>Drug Discovery Today: Technologies</i> , 2016 , 21-22, 67-73	7.1	2
22	Recent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory Acceptance. <i>Current Pharmacology Reports</i> , 2016 , 2, 161-169	5.5	147
21	Emerging Technologies and their Role in Regulatory Review. 2016 , 1-11		1
20	Rethinking on the concept of biomarkers in preclinical Alzheimer's disease. <i>Neurological Sciences</i> , 2016 , 37, 663-72	3.5	35
19	Novel approaches to pulmonary arterial hypertension drug discovery. <i>Expert Opinion on Drug Discovery</i> , 2016 , 11, 407-14	6.2	4
18	Open innovation in early drug discovery: roadmaps and roadblocks. <i>Drug Discovery Today</i> , 2016 , 21, 779-88	8.8	19
17	Managing Innovation to Maximize Value Along the Discovery-Translation-Application Continuum. <i>Clinical Pharmacology and Therapeutics</i> , 2017 , 101, 8-12	6.1	3
16	Qualification of safety biomarkers for use in drug development: What has been achieved and what is the path forward?. <i>Current Opinion in Toxicology</i> , 2017 , 4, 66-73	4.4	2
15	Drug development for breast, colorectal, and non-small cell lung cancers from 1979 to 2014. <i>Cancer</i> , 2017 , 123, 4672-4679	6.4	11
14	Scientific real-time research problem-solving and pharmaceutical innovation. <i>African Journal of Science, Technology, Innovation and Development</i> , 2017 , 9, 425-435	0.7	5
13	The Role of Public-Private Partnerships in Catalyzing the Critical Path. <i>Clinical and Translational Science</i> , 2017 , 10, 431-442	4.9	11
12	Reflections on the Future of Pharmaceutical Public-Private Partnerships: From Input to Impact. <i>Pharmaceutical Research</i> , 2017 , 34, 1985-1999	4.5	17

11	Prediction of human QT prolongation liability based on pre-clinical RNA expression profiles. 2017 ,		
10	Biologic Markers in Clinical Trials and Clinical Care. 2017 , 509-519		
9	Regulatory landscapes for biomarkers and diagnostic tests: Qualification, approval, and role in clinical practice. <i>Experimental Biology and Medicine</i> , 2018 , 243, 256-261	3.7	11
8	New Frontiers in Parkinson's Disease: From Genetics to the Clinic. <i>Journal of Neuroscience</i> , 2018 , 38, 9375-9382	5.9	24
7	Biomarkers of drug-induced acute kidney injury: a regulatory perspective. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2018 , 14, 929-936	5.5	9
6	Combining biorelevant in vitro and in silico tools to simulate and better understand the in vivo performance of a nano-sized formulation of aprepitant in the fasted and fed states. <i>European Journal of Pharmaceutical Sciences</i> , 2019 , 138, 105031	5.1	10
5	Nonlinear Mixed-Effects Model Development and Simulation Using nlmixr and Related R Open-Source Packages. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2019 , 8, 621-633	4.5	21
4	Advancing nonclinical innovation and safety in pharmaceutical testing. <i>Drug Discovery Today</i> , 2019 , 24, 624-628	8.8	3
3	Accelerating Therapeutics for Opportunities in Medicine: A Paradigm Shift in Drug Discovery. <i>Frontiers in Pharmacology</i> , 2020 , 11, 770	5.6	15
2	Huntington's Disease Regulatory Science Consortium: Accelerating Medical Product Development.. <i>Journal of Huntingtons Disease</i> , 2022 ,	1.9	0
1	The Role of fMRI in Drug Development: An Update. 2023 , 299-333		0